| Effects of Melatonin for Delirium in Elderly Acute Heart Failure Patients: A Randomized, Single-Center, Double-Blind, and Placebo-Controlled Trial 2022 · melatonin · Patients aged over 60 years after acute heart failure | 3 mg | 7 days | 248 |
| Effects of Melatonin on Postoperative Delirium After PCI in Elderly Patients: A Randomized, Single-Center, Double-Blind, Placebo-Controlled Trial 2021 · Mel group · Patients over age 60 admitted to intensive care units after PCI | 3 mg | 7 days | 148 |
| Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial 2023 · melatonin group · Adults aged 20 years or older with severe COVID-19 pneumonia admitted to the ICU | 10 mg | 7 days | 109 |
| The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients 2022 · melatonin group · Hospitalized adults aged 18–79 with confirmed severe COVID-19 | 10 mg | 2 weeks | 82 |
| The impact of melatonin on postoperative delirium in geriatric patients after colorectal surgery: a randomized placebo-controlled trial 2024 · Melatonin group · Elderly men and women undergoing elective colorectal cancer surgery under general anesthesia | 10 mg | 1 day | 50 |
| Role of melatonin in management of hypoxic ischaemic encephalopathy in newborns: A randomized control trial 2018 · intervention group · Newborns with gestational age of 34 weeks or higher and hypoxic ischaemic encephalopathy, presenting within 12 hours of birth | 10 mg | 1 day | 40 |
| Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin 1992 · MLT · Adults with metastatic nonsmall cell lung cancer that progressed after first-line cisplatin-containing chemotherapy; age and sex not reported | 10 mg | — | 31 |
| Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans 2011 · group B · H. pylori-positive adults aged 28–50 with gastric or duodenal ulcers | 10 mg | 3 weeks | 14 |
| Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension 1990 · IL-2 plus MLT · Metastatic renal cancer patients | 10 mg | 5 days | — |
| Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 1999 · MLT plus chemotherapy · Adults with metastatic solid tumours and poor clinical status; age and sex not reported | 20 mg | — | 124 |
| Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial 2003 · chemotherapy and melatonin · Patients with metastatic non-small cell lung cancer; age and sex not stated | 20 mg | — | 49 |
| A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state 1997 · chemotherapy plus melatonin · Adults with advanced non-small cell lung cancer and poor clinical status; age and sex not reported | 20 mg | — | 34 |
| Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations 2003 · CPT-11 plus MLT · Patients with metastatic colorectal cancer progressing after at least one previous 5-fluorouracil-containing chemotherapy line | 20 mg | 9 weeks | 14 |
| Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone 1996 · RT plus MLT · Patients with glioblastoma | 20 mg | — | 14 |
| Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms 2007 · chemotherapy plus MLT · Patients with metastatic solid tumors, including non-small cell lung cancer or gastrointestinal tumors | 20 mg | — | — |
| Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors 2008 · supportive care plus MLT · Patients with untreatable metastatic non-small-cell lung cancer or gastrointestinal tract tumors | 20 mg | — | — |
| Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors 2008 · MLT plus SC low-dose IL-2 · Patients with untreatable metastatic non-small-cell lung cancer or gastrointestinal tract tumors | 20 mg | 4 weeks | — |
| Protective Effects of Melatonin on Kidney Function Against Contrast Media-Induced Kidney Damage in Patients With Chronic Kidney Disease: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial 2025 · melatonin group · Patients with chronic kidney disease undergoing coronary angiography | 20 mg | 6 days | — |
| A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms 1994 · supportive care plus melatonin · Patients with brain metastases due to solid neoplasms | 20 mg | — | — |
| Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma 1996 · melatonin-treated group · Patients with melanoma surgically treated for regional node recurrence after lymph node relapse | 20 mg | — | — |
| Does Melatonin Improve Sleep Following Primary Total Hip Arthroplasty? A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · melatonin group · Patients undergoing primary elective total hip arthroplasty; age and sex not reported | 5 mg | 2 weeks | 75 |
| Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention 2016 · Melatonin 3 mg · Adults aged 18–65 with migraine, with or without aura | 3 mg | 12 weeks | 60 |
| Effect of melatonin on postoperative cognitive function in elderly patients submitted to transurethral resection of the prostate under spinal anesthesia 2025 · Melatonin group · Men aged over 60 with benign prostatic hyperplasia undergoing elective transurethral resection of the prostate under spinal anesthesia | 10 mg | 4 days | 58 |
| Comparison of the effects of preoperative melatonin or vitamin C administration on postoperative analgesia 2020 · group M (melatonin group) · Adults aged 18–65 years, ASA status I–II, undergoing elective major abdominal surgery | 6 mg | 1 day | 55 |
| Effect of add-on melatonin on seizure outcome, neuronal damage, oxidative stress, and quality of life in generalized epilepsy with generalized onset motor seizures in adults: A randomized controlled trial 2021 · test group · Adults with generalized epilepsy with generalized onset motor seizures | 3 mg | 8 weeks | 52 |
| Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial 2020 · 3 mg fast-release melatonin · Middle-aged patients with primary insomnia | 3 mg | 4 weeks | 51 |
| Efficacy of melatonin on sleep quality after laparoscopic cholecystectomy 2018 · Group A (melatonin group) · Adults aged 18–80 undergoing elective laparoscopic cholecystectomy | 3 mg | 3 days | 50 |
| Influence of Melatonin Treatment on Emotion, Sleep, and Life Quality in Perimenopausal Women: A Clinical Study 2023 · study group · Chinese women aged 45–55 with perimenopausal climacteric symptoms, sleep disorder, anxiety, and depression | 3 mg | 15 weeks | 50 |
| A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes 2014 · melatonin · Postmenopausal women with a history of primary breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ who had completed active cancer treatment | 3 mg | 120 days | 48 |
| Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial 2016 · Melatonin treatment · Children and adolescents aged 1 to 18 years with physician-diagnosed atopic dermatitis involving at least 5% of total body surface area and sleep disturbance | 3 mg | 4 weeks | 48 |
| Effect of melatonin supplementation on endothelial function in heart failure with reduced ejection fraction: A randomized, double-blinded clinical trial 2021 · melatonin group · Adults over 18 with stable heart failure with reduced ejection fraction (HFrEF) | 10 mg | 24 weeks | 46 |
| Effect of melatonin and gabapentin on anxiety and pain associated with retrobulbar eye block for cataract surgery: a randomized double-blind study 2013 · melatonin group (group M) · Patients undergoing cataract surgery; age and sex range not specified | 6 mg | 1 day | 40 |
| [Effect of melatonin on the daytime sleepiness side-effect of gabapentin in adults patients with neuropathic pain] 2019 · Group 1 (melatonin+) · Adults with neuropathic pain receiving gabapentin; age range and sex not specified | 3 mg | 30 days | 40 |
| Melatonin and sleep parameters in infertile women with endometriosis: first results from the triple-blind randomized controlled trial of administration of melatonin in chronic pelvic pain and sleep disturbance 2025 · melatonin group · Infertile women aged 18–45 with laparoscopy-confirmed endometriosis, chronic pelvic pain and sleep disturbances | 5 mg | 60 days | 40 |
| Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis?-A randomized controlled clinical trial 2019 · Melatonin group · Patients with generalized chronic periodontitis and primary insomnia; ages and sex not specified | 10 mg | 60 days | 38 |
| Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag 2001 · melatonin · Volunteers travelling eastward from Switzerland to the American continent and back across 6–9 time zones; age and sex not reported; jet lag | 5 mg | 5 days | 35 |
| Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial 2017 · Group A (melatonin) · Patients with chronic migraine | 3 mg | 60 days | 35 |
| The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial 2018 · melatonin supplements · children aged 6–12 years diagnosed with atopic dermatitis | 6 mg | 6 weeks | 35 |
| Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial 2023 · melatonin group · Adults older than 18 with mild to moderate gastroesophageal reflux disease symptoms | 3 mg | 4 weeks | 35 |
| The effects of melatonin on follicular oxidative stress and art outcomes in women with diminished ovarian reserve: a randomized controlled trial 2025 · Melatonin intervention group · Infertile women with diminished ovarian reserve undergoing their first assisted reproductive technology cycle; age range not reported | 3 mg | — | 35 |
| Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women 2015 · Group II · Overweight postmenopausal women aged 54–65 years with increased appetite | 5 mg | 24 weeks | 34 |
| The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study 2023 · Melatonin, patients with sleep disorders · Adults of unrestricted age and sex with IBS diagnosed by Rome IV criteria and sleep disorders | 6 mg | 8 weeks | 34 |
| The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study 2023 · Melatonin, patients without sleep disorders · Adults of unrestricted age and sex with IBS diagnosed by Rome IV criteria and without sleep disorders | 6 mg | 8 weeks | 34 |
| Comparison of the effect of melatonin, dexmedetomidine, and gabapentin on reduction of postoperative pain and anxiety following laminectomy: a randomized clinical trial 2022 · melatonin group (M) · Adults aged 40–60 years with ASA physical status I–II undergoing laminectomy at one or two levels | 10 mg | 1 day | 33 |
| A prospective randomized crossover trial investigating melatonin versus sleep deprivation for sleep induction in nap electroencephalography 2026 · melatonin · Children aged 6 years and older weighing at least 15 kg, with well-controlled epilepsy or suspected epilepsy and/or EEG abnormalities | 5 mg | 1 day | 33 |
| A Pilot of a Randomized Control Trial of Melatonin and Vitamin C for Mild-to-Moderate COVID-19 2022 · melatonin · Patients with mild-to-moderate COVID-19 symptoms | 10 mg | 2 weeks | 32 |
| Role of melatonin in attenuation of hemodynamic response to intubation and anesthetic requirements: a randomized, controlled, double-blind study 2023 · melatonin group · Adults aged 18–60 years, either sex, ASA physical status I/II, scheduled for elective laparoscopic cholecystectomy under general anesthesia | 3 mg | 1 day | 31 |
| Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial 2022 · melatonin · Patients with Parkinson's disease and subjective sleep complaints | 3 mg | 4 weeks | 31 |
| Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway 2007 · melatonin · Patients with subjective tinnitus; age and sex not reported | 3 mg | 30 days | 30 |
| Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis 2011 · group I · Adults aged 26–49 with left-sided ulcerative colitis in clinical remission for the previous 12 months | 5 mg | 1 year | 30 |
| The effects of melatonin on anxiety and pain scores of patients, intraocular pressure, and operating conditions during cataract surgery under topical anesthesia 2013 · M group · Adults aged 25–80 undergoing elective cataract surgery under topical anesthesia; ASA physical status I–III | 3 mg | 1 day | 30 |
| The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · melatonin · Diabetic hemodialysis patients aged 18–80 years | 10 mg | 12 weeks | 30 |
| Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2020 · melatonin group · Adults with Parkinson's disease; age and sex not specified | 10 mg | 12 weeks | 30 |
| Effect of add-on melatonin on seizure outcomes and quality of sleep in epilepsy with idiopathic generalized tonic-clonic seizures alone in adult patients: Cross-sectional, randomized, double-blind, placebo-controlled clinical trial 2023 · melatonin + valproic acid · Adults aged 18–60 with idiopathic generalized tonic-clonic seizures, receiving valproic acid | 3 mg | 8 weeks | 30 |
| The Effect of Melatonin on Reducing the Frequency and Severity of Migraine Attacks: A Double-Blind, Randomized Clinical Trial 2024 · Melatonin group · Adults aged 20–57 with migraine | 3 mg | 60 days | 30 |
| Effect of melatonin on tinnitus 1998 · melatonin treatment · Adults with subjective tinnitus | 3 mg | 30 days | 30 |
| Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag 2001 · combination melatonin/zolpidem · Volunteers travelling eastward from Switzerland to the American continent and back across 6–9 time zones; age and sex not reported; jet lag | 5 mg | 5 days | 29 |
| Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial 2019 · 10 mg melatonin · Women aged 18–40 years with polycystic ovary syndrome (PCOS) | 10 mg | 12 weeks | 29 |
| Melatonin supports nonsurgical periodontal treatment in patients with Type 2 diabetes mellitus and periodontitis: A randomized clinical trial 2024 · full-mouth scaling and root planing plus melatonin (fmSRP-mel) · Adults with type 2 diabetes mellitus and stage III/IV, grade C periodontitis | 6 mg | 30 days | 28 |
| Melatonin improves memory acquisition under stress independent of stress hormone release 2009 · melatonin · healthy young men | 3 mg | 1 day | 27 |
| Adjuvant use of melatonin for treatment of fibromyalgia 2011 · group B · Patients with fibromyalgia syndrome; age and sex distribution by arm not reported | 5 mg | 8 weeks | 27 |
| Adjuvant use of melatonin for treatment of fibromyalgia 2011 · group C · Patients with fibromyalgia syndrome; age and sex distribution by arm not reported | 3 mg | 8 weeks | 27 |
| Effect of Melatonin on Sleep in the Perioperative Period after Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · melatonin · Patients undergoing breast cancer surgery; adult age and sex details not stated | 6 mg | 2 weeks | 27 |
| Exogenous melatonin decreases circadian misalignment and body weight among early types 2021 · melatonin · Overweight female nurses working night shifts, with a mean age of 37.1 years and mean BMI of 29.9 kg/m²; analyses considered chronotype | 3 mg | 12 weeks | 27 |
| The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment 2019 · melatonin · Patients under methadone maintenance treatment; age and sex not specified | 10 mg | 12 weeks | 26 |
| The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial 2020 · melatonin group · Patients with non-alcoholic fatty liver disease; age range and sex not stated | 6 mg | 12 weeks | 24 |
| Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial 2022 · intervention group · Adults aged 18 years or older, male and non-pregnant female patients hospitalized with mild to moderate COVID-19 | 9 mg | 2 weeks | 24 |
| Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance 2003 · time-released melatonin · Adults aged 21–53 years, 9 men and 14 women; no condition stated | 6 mg | 1 day | 23 |
| Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam 2004 · time-released melatonin · Men and women aged 21–53 years; no specific condition stated | 6 mg | 1 day | 23 |
| Adjuvant use of melatonin for treatment of fibromyalgia 2011 · group D · Patients with fibromyalgia syndrome; age and sex distribution by arm not reported | 5 mg | 8 weeks | 23 |
| Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study 2001 · melatonin treatment group · patients with schizophrenia and tardive dyskinesia | 10 mg | 6 weeks | 22 |
| Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study 2009 · melatonin · Adults over 65 with a history of sleep disorder complaints; 7 men and 15 women enrolled | 5 mg | 60 days | 22 |
| The effect of melatonin in patients with fibromyalgia: a pilot study 2000 · melatonin treatment · Adults with fibromyalgia; age range and sex not specified | 3 mg | 4 weeks | 21 |
| Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial 2014 · melatonin · Adults aged 18 years or older with fibromyalgia, refractory to their current treatment | 10 mg | 6 weeks | 21 |
| Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial 2014 · amitriptyline + melatonin · Adults aged 18 years or older with fibromyalgia, refractory to their current treatment | 10 mg | 6 weeks | 21 |
| Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial 2001 · melatonin · Children aged 6–12 years with chronic sleep onset insomnia lasting more than 1 year | 5 mg | 4 weeks | 20 |
| Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia 2003 · 3.0 mg melatonin · People with intellectual disability and sleep deficits/insomnia; age and sex not reported | 3 mg | 7 days | 20 |
| Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study 2005 · melatonin · Adults aged 20–64 with irritable bowel syndrome and sleep disturbances | 3 mg | 2 weeks | 20 |
| Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia 2009 · melatonin group · Patients undergoing cataract surgery under topical anesthesia; age and sex not stated | 10 mg | 1 day | 20 |
| [Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam] 2012 · Group 1 · Adults with Parkinson's disease without dementia and sleep-disorder complaints; mean age 67.3 years; 15 males and 23 females across the study | 3 mg | 6 weeks | 20 |
| Premedication with oral alprazolam and melatonin combination: a comparison with either alone--a randomized controlled factorial trial 2014 · Group one: combination of alprazolam and melatonin · Patients aged 18–65 with anxiety scheduled for general anesthesia for laparoscopic cholecystectomy | 3 mg | 1 day | 20 |
| Premedication with oral alprazolam and melatonin combination: a comparison with either alone--a randomized controlled factorial trial 2014 · Group three: melatonin · Patients aged 18–65 with anxiety scheduled for general anesthesia for laparoscopic cholecystectomy | 3 mg | 1 day | 20 |
| Comparison of the Effects of Melatonin and Oxazepam on Anxiety Levels and Sleep Quality in Patients With ST-Segment-Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial 2018 · melatonin group · Patients with ST-segment-elevation myocardial infarction following primary percutaneous coronary intervention | 3 mg | — | 20 |
| The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial 2022 · Group B (5 mg melatonin) · Adults aged 35–70 undergoing lumbar laminectomy and discectomy | 5 mg | 1 day | 20 |
| The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial 2022 · Group C (10 mg melatonin) · Adults aged 35–70 undergoing lumbar laminectomy and discectomy | 10 mg | 1 day | 20 |
| Melatonin administered postoperatively lowers oxidative stress and inflammation and significantly recovers heart function in patients undergoing CABG surgery 2025 · Group 1 (ML1) · Adults aged 30–70 undergoing elective CABG surgery | 5 mg | 60 days | 20 |
| Melatonin administered postoperatively lowers oxidative stress and inflammation and significantly recovers heart function in patients undergoing CABG surgery 2025 · Group 2 (ML2) · Adults aged 30–70 undergoing elective CABG surgery | 10 mg | 60 days | 20 |
| Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures 1999 · melatonin · 20 young healthy adults aged about 23.5 years, male and female | 5 mg | 1 day | 20 |
| The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial 2022 · Group A (3 mg melatonin) · Adults aged 35–70 undergoing lumbar laminectomy and discectomy | 3 mg | 1 day | 19 |
| Randomized placebo-controlled field study of the effects of bright light and melatonin in adaptation to night work 2007 · melatonin · 17 oil-rig shift workers; age, sex, and medical condition not reported | 3 mg | 8 days | 17 |
| The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy 2007 · oral melatonin · Women undergoing abdominal hysterectomy, ASA physical status I-II; age not reported | 10 mg | 1 day | 17 |
| The effects of melatonin on colonic transit time in normal controls and IBS patients 2009 · Healthy controls · Healthy adults; age and sex not reported | 3 mg | 30 days | 17 |
| The effects of melatonin on colonic transit time in normal controls and IBS patients 2009 · Melatonin phase · Adults with irritable bowel syndrome; age and sex not reported | 3 mg | 8 weeks | 17 |
| Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial 2022 · Melatonin treatment · Men aged 40–70 years with type 2 diabetes; Caucasian, with BMI 25–35 kg/m² at diagnosis | 10 mg | 12 weeks | 17 |
| Melatonin reduces arousal and startle responsiveness without influencing startle habituation or affective startle modulation in young women 2008 · melatonin · healthy young women | 4 mg | 1 day | 16 |
| Effect of daytime oral melatonin administration on neurobehavioral performance in humans 1998 · Melatonin · Healthy young adults, mean age 22.4 years; 10 males and 6 females | 5 mg | 1 day | 16 |
| Melatonin treatment for age-related insomnia 2001 · 3.0 mg melatonin · Adults over 50 with actigraphically confirmed decreased sleep efficiency (insomniac subjects) | 3 mg | 7 days | 15 |
| Melatonin treatment for age-related insomnia 2001 · 3.0 mg melatonin · Adults over 50 who slept normally | 3 mg | 7 days | 15 |
| Melatonin and jet lag: confirmatory result using a simplified protocol 1992 · melatonin · Travelers on an eastward flight from North America to France; age and sex not stated | 8 mg | 4 days | 15 |
| 12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial 2025 · melatonin group (MG) · Persons with multiple sclerosis | 3 mg | 12 weeks | 15 |
| Effects of Melatonin Supplementation on Muscle Strength, Manual Dexterity, and Postural Balance in Patients Living with Multiple sclerosis - A Randomized Controlled Trial 2025 · melatonin group (MG) · Patients with multiple sclerosis; age and sex not reported | 3 mg | 12 weeks | 15 |
| Melatonin influences human balance 1999 · 10 mg melatonin study · healthy volunteers; age and sex not reported | 10 mg | 1 day | 14 |
| Melatonin ingestion after exhaustive late-evening exercise attenuate muscle damage, oxidative stress, and inflammation during intense short term effort in the following day in teenage athletes 2020 · melatonin · Healthy-trained male teenage athletes | 10 mg | 1 day | 14 |
| Melatonin and zopiclone as pharmacologic aids to facilitate crew rest 2001 · 10 mg melatonin · 13 transport aircrew subjects; age and sex not reported; no condition specified | 10 mg | 1 day | 13 |
| Melatonin and zopiclone: the relationship between sleep propensity and body temperature 2002 · melatonin · 12 healthy young adults, 20.3 ± 0.6 years; 7 male and 5 female | 5 mg | 1 day | 12 |
| Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial 2008 · Melatonin · Critically ill adults with acute respiratory failure requiring mechanical ventilation and tracheostomy to assist weaning | 10 mg | 4 days | 12 |
| Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease 2008 · melatonin · Patients with moderate to very severe COPD; age and sex not specified | 3 mg | 3 weeks | 12 |
| Melatonin attenuates the vestibulosympathetic but not vestibulocollic reflexes in humans: selective impairment of the utricles 2010 · melatonin, study 1 · healthy adults aged 28 ± 1 years; 6 men and 6 women | 3 mg | 1 day | 12 |
| Melatonin attenuates the skin sympathetic nerve response to mental stress 2013 · melatonin · 12 healthy subjects | 3 mg | 1 day | 12 |
| Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study 2015 · Melatonin · Pre-pubertal children aged 6–11 years with epilepsy and sleep difficulties | 9 mg | 4 weeks | 11 |
| Daytime sleep and performance following a zolpidem and melatonin cocktail 2005 · zolpidem 0 mg plus melatonin 5 mg · Adults; sex and health condition not specified | 5 mg | 1 day | 10 |
| Daytime sleep and performance following a zolpidem and melatonin cocktail 2005 · zolpidem 5 mg plus melatonin 5 mg · Adults; sex and health condition not specified | 5 mg | 1 day | 10 |
| Daytime sleep and performance following a zolpidem and melatonin cocktail 2005 · zolpidem 10 mg plus melatonin 5 mg · Adults; sex and health condition not specified | 5 mg | 1 day | 10 |
| Daytime sleep and performance following a zolpidem and melatonin cocktail 2005 · zolpidem 20 mg plus melatonin 5 mg · Adults; sex and health condition not specified | 5 mg | 1 day | 10 |
| Melatonin attenuates the vestibulosympathetic but not vestibulocollic reflexes in humans: selective impairment of the utricles 2010 · melatonin, study 2 · healthy adults aged 26 ± 1 years; 4 men and 6 women | 3 mg | 1 day | 10 |
| Effect of melatonin on seizure frequency in intractable epilepsy: a pilot study 2012 · melatonin phase · Patients aged 9 to 32 years with intractable epilepsy | 10 mg | 3 weeks | 10 |
| Melatonin ingestion after exhaustive late-evening exercise improves sleep quality and quantity, and short-term performances in teenage athletes 2018 · MEL-10 mg · Male adolescent athletes, mean age 15.4 years, described as healthy | 10 mg | 1 day | 10 |
| Daytime melatonin and light independently affect human alertness and body temperature 2019 · Melatonin intervention · Healthy adults aged 20–30 years, 5 female and 5 male, without reported health or sleep problems | 5 mg | 1 day | 10 |
| Melatonin supplementation improves psychomotor and physical performance in collegiate student-athletes following a sleep deprivation night 2021 · melatonin · Trained male collegiate student-athletes, mean age 20 years, tested under sleep-deprivation conditions | 6 mg | 1 day | 10 |
| Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups 1996 · oral melatonin · Cluster headache patients (2 with primary chronic cluster headache and 18 with episodic cluster headache); age and sex not reported | 10 mg | 2 weeks | 10 |
| Complex effects of melatonin on human circadian rhythms in constant dim light 1997 · Melatonin · 10 normal, healthy males | 5 mg | 15 days | 10 |
| Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel 2004 · melatonin (Mlt) · Nine subjects after a seven-time-zone eastbound flight; age and sex not reported | 5 mg | 5 days | 9 |
| A preliminary study of melatonin in irritable bowel syndrome 2007 · melatonin · Adults aged 18 to 65 with irritable bowel syndrome | 3 mg | 8 weeks | 9 |
| Melatonin improves sleep and reduces nitrite in the exhaled breath condensate in cystic fibrosis--a randomized, double-blind placebo-controlled study 2010 · 3 mg melatonin · Clinically stable patients with cystic fibrosis; mean age 16.6 years | 3 mg | 3 weeks | 9 |
| Delayed sleep phase syndrome response to melatonin 1991 · melatonin · 8 subjects with delayed sleep phase syndrome attending a sleep disorders clinic | 5 mg | 4 weeks | 8 |
| A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder 2010 · melatonin · Males with polysomnographically confirmed REM sleep behaviour disorder (mean age 54 years) | 3 mg | 4 weeks | 8 |
| Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3 mg melatonin 2014 · melatonin · Adults with complete tetraplegia; mean age 49.5 years | 3 mg | 3 weeks | 8 |
| Therapeutic benefit of melatonin in refractory central serous chorioretinopathy 2015 · melatonin · Patients with chronic central serous chorioretinopathy (CSCR), with visual acuity of 20/40 or worse in the affected eye or an incapacitating scotoma | 9 mg | 30 days | 8 |
| A relationship between heat loss and sleepiness: effects of postural change and melatonin administration 1997 · Melatonin administration · Eight healthy young men | 5 mg | 1 day | 8 |
| Actigraphy in agitated patients with dementia. Monitoring treatment outcomes 2007 · 3 mg melatonin · Patients with probable dementia of the Alzheimer type and agitated behaviour | 3 mg | 2 weeks | 7 |
| The hypnotic effects of melatonin treatment on diurnal sleep in humans 1999 · melatonin · six healthy male students | 10 mg | 1 day | 6 |
| Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam 1999 · melatonin · adult women undergoing anaesthesia; age range and condition not specified | 5 mg | 1 day | — |
| A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome 2001 · melatonin · Patients with delayed sleep phase syndrome | 5 mg | 4 weeks | — |
| The effects of bright light and nighttime melatonin administration on cardiac activity 2001 · melatonin · 16 young healthy subjects; age range and sex not stated | 5 mg | 1 day | — |
| Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial 2003 · melatonin · Children aged 6–12 years with idiopathic chronic sleep-onset insomnia | 5 mg | 4 weeks | — |
| Melatonin in patients with reduced REM sleep duration: two randomized controlled trials 2004 · melatonin · Adults, five women and nine men, mean age 50 years, with unselected neuropsychiatric sleep disorders and reduced REM sleep duration | 3 mg | 4 weeks | — |
| Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial 2004 · oral synthetic fast-release MLT · Children, adolescents and young adults aged 3.6–26 years with mental retardation and wake-sleep disorder, most with epileptic seizures | 3 mg | — | — |
| Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance 2004 · melatonin group · Patients undergoing laparoscopic cholecystectomy; age and sex not specified | 5 mg | 1 day | — |
| Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study 2005 · melatonin · Female patients with irritable bowel syndrome meeting Rome II criteria | 3 mg | 8 weeks | — |
| Melatonin premedication and the induction dose of propofol 2007 · M3 group · Adults undergoing different surgical procedures | 3 mg | 1 day | — |
| Melatonin premedication and the induction dose of propofol 2007 · M5 group · Adults undergoing different surgical procedures | 5 mg | 1 day | — |
| Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study 2007 · melatonin · Patients with Parkinson's disease, Hoehn & Yahr stages I to III; age and sex not specified | 3 mg | 4 weeks | — |
| Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial 2007 · Melatonin · Adults enrolled in a benzodiazepine withdrawal programme at a methadone maintenance clinic | 5 mg | 6 weeks | — |
| Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease 2008 · LM (morning bright-light exposure plus evening melatonin) · Institutionalized adults with probable Alzheimer’s disease and rest–activity rhythm disruption; ages 60–100, both sexes | 5 mg | 10 weeks | — |
| The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study) 2009 · melatonin · Haemodialysis patients; six women, median age 71 years | 3 mg | 6 weeks | — |
| Melatonin: can it stop the ringing? 2011 · melatonin · Adults with chronic tinnitus | 3 mg | 30 days | — |
| Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study 2014 · melatonin group · Patients with first-episode schizophrenia eligible for olanzapine treatment | 3 mg | 8 weeks | — |
| Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial 2015 · melatonin · Critically ill adults in the ICU, mechanically ventilated for more than 48 hours and with Simplified Acute Physiology Score II greater than 32 | 6 mg | — | — |
| Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial 2016 · 3 mg melatonin nightly · Postmenopausal women; age range not reported | 3 mg | 1 year | — |
| Melatonin premedication versus placebo in wisdom teeth extraction: a randomised controlled trial 2015 · melatonin · Adults aged 21–65 undergoing elective extraction of all four wisdom teeth under general anaesthesia; ASA physical status I or II | 6 mg | 1 day | — |
| Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery 2016 · low dose melatonin treatment group (M1) · Patients undergoing elective coronary artery bypass graft surgery | 10 mg | — | — |
| Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial 2020 · melatonin group · Patients with acute manic episodes associated with bipolar disorder | 6 mg | 6 weeks | — |
| The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial 2020 · melatonin group · Adults admitted to the ICU and receiving analgesics and/or sedatives | 10 mg | 7 days | — |
| Evaluation of Antipruritic Effect of Melatonin on Hemodialysis Patients with Uremic Pruritus, A Double-Blind, Randomized, Crossover Trial 2021 · melatonin period · Adults receiving hemodialysis with uremic pruritus | 5 mg | 2 weeks | — |
| Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial 2021 · melatonin group · Patients with rheumatoid arthritis; age and sex not reported | 6 mg | 12 weeks | — |
| The effect of Melatonin on Improving the benign Prostatic Hyperplasia Urinary Symptoms, a Randomized Clinical Trial 2022 · treatment group · men aged 50 years or older with benign prostatic hyperplasia symptoms and IPSS ≥ 8 | 3 mg | 30 days | — |
| High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults 2022 · high-dose melatonin condition · Healthy adults aged 55–78 years without major sleep complaints; 13 women and 11 men across the study | 5 mg | 12 days | — |
| The Effect of Melatonin on Analgesia, Anxiety, and Intraocular Pressure (IOP) in Cataract Surgery Under Topical Anesthesia 2023 · melatonin group · Patients aged 50 to 80 undergoing cataract surgery under topical anesthesia | 3 mg | 1 day | — |
| The effect of treatment with melatonin on primary school aged children with difficulty in initiation and maintenance of sleep 2022 · intervention group · Children aged 7–12 with sleep problems/insomnia | 3 mg | 30 days | — |
| Study of Exogenous Melatonin as a Treatment Modality for Sleep and Psychiatric Disorders in Hemodialysis Patients 2022 · melatonin-treated group · Adults with stable hemodialysis and sleep disorders (PSQI score ≥5); age and sex not reported | 3 mg | 90 days | — |
| Targeting Side Effects Associated with Androgen Deprivation Therapy Using Melatonin: A Randomized Trial on Hot Flashes and Sexual Health in Prostate Cancer Patients 2026 · melatonin · Prostate cancer patients experiencing hot flashes or sexual dysfunction due to androgen deprivation therapy | 6 mg | 4 weeks | — |
| Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil 1996 · melatonin plus placebo · young healthy adult males | 3 mg | 1 day | — |
| Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil 1996 · melatonin plus flumazenil · young healthy adult males | 3 mg | 1 day | — |
| Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag 1998 · 5-mg fast-release (FR) formulation · Volunteers who had flights over 6 to 8 time zones; age and sex not stated | 5 mg | 4 days | — |
| Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial 2011 · melatonin group · Adults aged 65 years or over admitted through the emergency department to a medical unit | 500 mcg | 2 weeks | 72 |
| A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour 1995 · IL-2 plus melatonin · Adults with untreatable metastatic solid tumours for whom no standard therapy was available | 40 mg | 4 weeks | 52 |
| Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin 1996 · Melatonin with IL-2 · Adults with advanced solid tumours receiving IL-2 cancer biotherapy | 40 mg | 5 weeks | 45 |
| A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma 1994 · IL-2 + MLT · Adults aged 36–74 with advanced solid tumours other than renal cell cancer and melanoma | 40 mg | — | 41 |
| A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer 1994 · Immunotherapy · Patients with locally advanced or metastatic non-small cell lung cancer | 40 mg | — | 31 |
| Comparison Between Efficacy of Melatonin and Diazepam for Prevention of Recurrent Simple Febrile Seizures: A Randomized Clinical Trial 2019 · melatonin group · Children aged 6–50 months with recurrent simple febrile seizures | 0.9 mg/kg | 3 days | 30 |
| A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates 1995 · low-dose subcutaneous IL-2 plus melatonin · Adults with metastatic colorectal cancer who did not respond or progressed after first-line 5-FU and folates | 40 mg | 4 weeks | 25 |
| Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin 1996 · Melatonin with TNF · Adults with advanced solid tumours receiving TNF cancer biotherapy | 40 mg | 12 days | 23 |
| Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study 2015 · melatonin/hypothermia group · Term newborns with hypoxic-ischemic encephalopathy | 10 mg/kg | 5 days | 15 |
| Beneficial Effects of Adjuvant Melatonin in Minimizing Oral Mucositis Complications in Head and Neck Cancer Patients Receiving Concurrent Chemoradiation 2017 · Melatonin group · Adults with head and neck cancer receiving concurrent chemoradiation | 20 mg | 7 weeks | — |
| Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety 2010 · prolonged-release melatonin (PRM) group · Men and women aged 18–80 years with primary insomnia; efficacy was also assessed in low melatonin excretors and adults aged 65–80 years. | 2 mg | 29 weeks | 373 |
| Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes 2007 · PR-melatonin · Males and females aged 55–80 years with primary insomnia | 2 mg | 3 weeks | 177 |
| A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments 2023 · intervention group (oral melatonin) · Female patients with stage I–III invasive breast cancer receiving adjuvant chemotherapy and radiotherapy | 18 mg | 125 weeks | 102 |
| Exogenous melatonin's effect on salivary cortisol and amylase: A randomized controlled trial 2024 · Melatonin group · Healthy adult volunteers aged 19–75, without underlying disease; men and women | 2 mg | 1 day | 64 |
| Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life 2019 · PedPRM · Children and adolescents aged 2–17.5 years with autism spectrum disorder or Smith-Magenis syndrome and chronic sleep disturbances | 2 mg | 13 weeks | 58 |
| Melatonin treatment has consistent but transient beneficial effects on sleep measures and pain in patients with severe chronic pain: the DREAM-CP randomised controlled trial 2024 · Melatonin treatment period (Circadin™) · Adults with severe chronic non-malignant pain of at least 3 months’ duration; ages 24–79 in the enrolled groups | 2 mg | 6 weeks | 58 |
| Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder 2021 · PedPRM group · Children and adolescents aged 2–17.5 years with autism spectrum disorder or Smith-Magenis syndrome and impaired sleep | 2 mg | 104 weeks | 51 |
| Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial 2025 · intervention group · Women aged 18–65 with breast cancer receiving adjuvant radiotherapy | 20 mg | — | 50 |
| Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder 2021 · Placebo group, then open-label PedPRM · Children and adolescents aged 2–17.5 years with autism spectrum disorder or Smith-Magenis syndrome and impaired sleep | 2 mg | 104 weeks | 44 |
| Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial 2014 · PRM (prolonged-release melatonin) · Adults aged 50–85 with mild to moderate Alzheimer’s disease receiving stable standard Alzheimer’s therapy | 2 mg | 24 weeks | 39 |
| A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments 2021 · intervention group (oral melatonin) · Women with stage I–III invasive breast cancer receiving adjuvant chemotherapy and radiotherapy | 18 mg | 25 weeks | 38 |
| Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach 1999 · Melatonin group, period 2 · Adults with insomnia receiving benzodiazepine therapy; age and sex not specified | 2 mg | 6 weeks | 34 |
| Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial 2018 · melatonin treatment · Adults aged 18–65 with traumatic brain injury and chronic insomnia | 2 mg | 4 weeks | 33 |
| Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial 2018 · melatonin treatment · Adults aged 18–65 with traumatic brain injury and chronic insomnia | 2 mg | 4 weeks | 33 |
| Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway 2007 · sulpiride plus melatonin · Patients with subjective tinnitus; age and sex not reported | 3 mg | 30 days | 30 |
| The effect of long-term melatonin supplementation on psychosomatic disorders in postmenopausal women 2018 · Group II — melatonin · Postmenopausal women aged 51–64 years | 8 mg | 1 year | 30 |
| Effectiveness of melatonin for the treatment of nocturia: a randomized controlled trial 2023 · treatment · women aged over 55 years with nocturia | 2 mg | 2 weeks | 30 |
| Effects of melatonin administration on daytime sleep after simulated night shift work 2001 · Melatonin session · Healthy adults aged 18–37 years, women and men, without stated medical, psychiatric, or sleep disorders, undergoing simulated night-shift work | 1.8 mg | 2 days | 21 |
| Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs 1997 · controlled-release melatonin · Elderly people with insomnia, low melatonin output, and benzodiazepine treatment | 2 mg | 3 weeks | 21 |
| Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement 2004 · melatonin · Older men with urodynamically confirmed bladder outflow obstruction and nocturia | 2 mg | 4 weeks | 20 |
| Effects of melatonin and rilmazafone on nocturia in the elderly 2007 · melatonin · Elderly patients with nocturia | 2 mg | 4 weeks | 20 |
| Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial 2016 · Prolonged-release melatonin (PRM) · Adults aged 18 years or older with schizophrenia, schizoaffective disorder, or euthymic bipolar disorder, receiving antipsychotic treatment and long-term benzodiazepine or benzodiazepine-like treatment | 2 mg | 24 weeks | 20 |
| Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study 2021 · melatonin group · Women aged 55 years and older with insomnia (PSQI ≥5) | 2 mg | 6 weeks | 19 |
| Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach 1999 · Melatonin group, period 1 · Adults with insomnia receiving benzodiazepine therapy; age and sex not specified | 2 mg | 6 weeks | 18 |
| Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial 2020 · Melatonin · Women aged 18–75 with breast cancer scheduled for their first cycle of adjuvant chemotherapy | 20 mg | 10 days | 18 |
| Improvement of sleep quality in elderly people by controlled-release melatonin 1995 · controlled-release melatonin · Elderly people aged 76 years on average with insomnia and chronic illnesses | 2 mg | 3 weeks | 12 |
| Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects 2007 · prolonged-release melatonin · Adults aged 55 years and older with primary insomnia | 2 mg | 3 weeks | — |
| Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial 2008 · Melatonin with dim light · Elderly group-care residents, mean age 85.8 years; 90% female and 87% with dementia | 2.5 mg | 1278 days | — |
| Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial 2008 · Melatonin with bright light · Elderly group-care residents, mean age 85.8 years; 90% female and 87% with dementia | 2.5 mg | 1278 days | — |
| The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia 2009 · prolonged-release melatonin (PRM) · Patients aged ≥55 years with primary insomnia; sex not specified | 2 mg | 3 weeks | — |
| Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response 2011 · PRM (prolonged-release melatonin) · Males and females aged 18–80 years with primary insomnia and mean nightly sleep latency greater than 20 minutes | 2 mg | 29 weeks | — |
| Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial 2012 · 2.5 mg melatonin · Adults aged 45–64 with hypertension treated with atenolol or metoprolol | 2.5 mg | 3 weeks | — |
| Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery 2016 · high dose melatonin treatment group (M2) · Patients undergoing elective coronary artery bypass graft surgery | 20 mg | — | — |
| Melatonin supplementation may benefit patients with acute ischemic stroke not eligible for reperfusion therapies: Results of a pilot study 2022 · melatonin · Patients with acute ischemic stroke not eligible for reperfusion therapy; age and sex not reported | 20 mg | 5 days | — |
| Is there a role for melatonin in the treatment of neoplastic cachexia? 1996 · supportive care plus MLT · patients with untreatable metastatic solid tumours | 20 mg | 90 days | — |
| Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag 1998 · 2-mg controlled-release (CR) formulation · Volunteers who had flights over 6 to 8 time zones; age and sex not stated | 2 mg | 4 days | — |
| Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study 2000 · melatonin · Mild to moderate essential hypertensive outpatients; age and sex not reported | 5 mg | 4 weeks | 47 |
| Study on the Effects of Melatonin on Glycemic Control and Periodontal Parameters in Patients with Type II Diabetes Mellitus and Periodontal Disease 2021 · study group · Adults with type 2 diabetes and chronic periodontitis; mean age 53.24 years | 3 mg | 8 weeks | 27 |
| Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial 2021 · intervention group · Men and women aged 30–60 with type 2 diabetes mellitus diagnosed more than 5 years earlier | 3 mg | 8 weeks | 25 |
| Blood pressure response to melatonin in type 1 diabetes 2004 · melatonin treatment phase · Adolescents aged 14–18: 11 normotensive, normoalbuminuric patients with type 1 diabetes and 10 healthy controls | 5 mg | 7 days | 21 |
| Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial 2014 · melatonin · Adults with bipolar disorder or schizophrenia treated with second-generation antipsychotics | 5 mg | 8 weeks | 20 |
| Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial 2015 · 3 mg melatonin · Postmenopausal women with osteopenia, mean age 63 years (range 56–73) | 3 mg | 1 year | 20 |
| Prolonged melatonin administration decreases nocturnal blood pressure in women 2005 · slow-release melatonin · Women aged 47 to 63 years with normal blood pressure or treated essential hypertension | 3 mg | 3 weeks | 18 |
| [Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II] 1999 · Group 1: melatonin alone · Patients with essential hypertension stage II; age and sex not reported | 6 mg | 10 days | 10 |
| Melatonin supplementation reduces nighttime blood pressure but does not affect blood pressure reactivity in normotensive adults on a high-sodium diet 2023 · HSD + MEL · Healthy normotensive men and women, mean age 26.5 years, on a high-sodium diet | 10 mg | 10 days | — |
| Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial 2014 · Melatonin · Adults undergoing elective surgery for abdominal aortic aneurysm | 10 mg | 4 days | 26 |
| The effects of melatonin premedication on propofol and thiopental induction dose-response curves: a prospective, randomized, double-blind study 2006 · Melatonin · Adults with ASA physical status I undergoing anesthetic induction | 0.2 mg/kg | 1 day | 100 |
| Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial 2018 · melatonin · Males and females aged 16–65 with delayed sleep-wake phase disorder and confirmed circadian delay | 500 mcg | 4 weeks | 58 |
| POTENTIAL USE OF MELATONIN IN PROCEDURAL ANXIETY AND PAIN IN CHILDREN UNDERGOING BLOOD WITHDRAWAL 2015 · melatonin · Children aged 1–14 years undergoing blood withdrawal | 0.5 mg/kg | 1 day | 30 |
| Comparing Intranasal Midazolam, Oral Melatonin, and Distraction Cards for Pain and Stress Management in Pediatric Intravenous Line Insertion: A Randomized Controlled Trial 2026 · Group 3: Administration of Oral Melatonin · Children aged 3–10 years with mild to moderate dehydration related to gastroenteritis undergoing intravenous line insertion in an emergency department | 0.5 mg/kg | 1 day | 30 |
| Oral melatonin, dexmedetomidine, and midazolam for prevention of postoperative agitation in children 2011 · group ML · Children aged 3–9 years undergoing esophageal dilatation under general anesthesia | 0.1 mg/kg | 1 day | 25 |
| The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial 2011 · supplemented group · Long-term care facility residents with primary insomnia; mean age 78.3 ± 3.9 years; sex not reported | 5 mg | 8 weeks | 22 |
| Melatonin treatment effects on adolescent students' sleep timing and sleepiness in a placebo-controlled crossover study 2012 · Melatonin · Students aged 14–19 years with sleep-onset difficulties during school weeks | 1 mg | 6 days | 21 |
| Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia 2003 · 0.1 mg melatonin · People with intellectual disability and sleep deficits/insomnia; age and sex not reported | 100 mcg | 7 days | 20 |
| A pilot study on the melatonin treatment in patients with early septic shock: results of a single-center randomized controlled trial 2022 · melatonin group · Adults aged 18–75 with early septic shock | 50 mg | 5 days | 20 |
| Melatonin treatment for age-related insomnia 2001 · 0.1 mg melatonin · Adults over 50 with actigraphically confirmed decreased sleep efficiency (insomniac subjects) | 100 mcg | 7 days | 15 |
| Melatonin treatment for age-related insomnia 2001 · 0.3 mg melatonin · Adults over 50 with actigraphically confirmed decreased sleep efficiency (insomniac subjects) | 300 mcg | 7 days | 15 |
| Melatonin treatment for age-related insomnia 2001 · 0.1 mg melatonin · Adults over 50 who slept normally | 100 mcg | 7 days | 15 |
| Melatonin treatment for age-related insomnia 2001 · 0.3 mg melatonin · Adults over 50 who slept normally | 300 mcg | 7 days | 15 |
| Effect of oral melatonin and wearing earplugs and eye masks on nocturnal sleep in healthy subjects in a simulated intensive care unit environment: which might be a more promising strategy for ICU sleep deprivation? 2015 · NLM (NL plus melatonin) · Healthy adults aged 24–64 years, men and women, exposed to simulated ICU noise and light | 1 mg | 4 days | 10 |
| The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study 2000 · 0.05 mg/kg melatonin group · Adult women undergoing surgery and receiving anesthetic premedication | 0.05 mg/kg | 1 day | — |
| The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study 2000 · 0.1 mg/kg melatonin group · Adult women undergoing surgery and receiving anesthetic premedication | 0.1 mg/kg | 1 day | — |
| Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study 2004 · melatonin · healthy elderly subjects | 1 mg | 4 weeks | — |
| Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial 2016 · 1 mg melatonin nightly · Postmenopausal women; age range not reported | 1 mg | 1 year | — |
| The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: A randomized controlled trial 2017 · melatonin · Patients older than 65 years (mean age 74.5 years; 53 male and 86 female) scheduled for hip arthroplasty | 1 mg | 6 days | — |
| Should Melatonin Be Used as an Alternative Sedative and Anxiolytic Agent in Mandibular Third Molar Surgery? 2019 · group M · Patients undergoing impacted third molar surgery | 0.4 mg/kg | 1 day | — |
| Melatonin as host modulating agent supporting nonsurgical periodontal therapy in patients affected by untreated severe periodontitis: A preliminary randomized, triple-blind, placebo-controlled study 2020 · melatonin group · People with untreated severe (stage III) periodontitis; age range and sex not reported | 1 mg | 30 days | — |
| High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults 2022 · low-dose melatonin condition · Healthy adults aged 55–78 years without major sleep complaints; 13 women and 11 men across the study | 300 mcg | 12 days | — |
| Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep 2022 · melatonin · Adults aged 18–55 with ADHD and delayed sleep phase syndrome | 500 mcg | 3 weeks | — |
| Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep 2022 · melatonin plus bright light therapy · Adults aged 18–55 with ADHD and delayed sleep phase syndrome | 500 mcg | 3 weeks | — |
| Randomized Clinical Trial of Antioxidant Therapy Patients with Septic Shock and Organ Dysfunction in the ICU: SOFA Score Reduction by Improvement of the Enzymatic and Non-Enzymatic Antioxidant System 2023 · Group 4 (MT) · Adults older than 18 years of any gender with septic shock admitted to the ICU | 50 mg | 5 days | — |
| Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects 2023 · Group 4 (MT) · Adults over 18 years of any gender with septic shock | 50 mg | 5 days | — |
| Low dose melatonin improves sleep in healthy middle-aged subjects 1996 · 0.3 mg melatonin · Healthy middle-aged volunteers | 300 mcg | 1 day | — |
| Low dose melatonin improves sleep in healthy middle-aged subjects 1996 · 1.0 mg melatonin · Healthy middle-aged volunteers | 1 mg | 1 day | — |
| Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag 1998 · 0.5-mg fast-release (FR) formulation · Volunteers who had flights over 6 to 8 time zones; age and sex not stated | 500 mcg | 4 days | — |
| Daily Melatonin Administration Attenuates Age-Dependent Disturbances of Cardiovascular Rhythms 2016 · melatonin group · Men and women aged 63–91 years, normotensive or hypertensive | 1.5 mg | 2 weeks | 63 |
| Melatonin Supplementation Alleviates Bone Mineral Density Decline and Circulating Oxidative Stress in Iron-Overloaded Thalassemia Patients 2025 · melatonin group · Adults with thalassemia, osteopenia, and iron overload; mean age 30.8 years | 20 mg | 1 year | 21 |
| Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension 2004 · Repeated melatonin · Men with untreated essential hypertension | 2.5 mg | 3 weeks | 16 |
| Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension 2004 · Acute melatonin · Men with untreated essential hypertension | 2.5 mg | 1 day | 16 |
| [Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II] 1999 · Group 2: aceten plus melatonin · Patients with essential hypertension stage II; age and sex not reported | 6 mg | 10 days | 10 |
| The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial 2020 · Study group · Women undergoing ICSI | 2 mg | 26 weeks | 50 |
| Safety and efficacy of melatonin supplementation as an add-on treatment for infantile epileptic spasms syndrome: A randomized, placebo-controlled, double-blind trial 2024 · Melatonin group · Children aged 3 months to 2 years with infantile epileptic spasms syndrome | 3 mg | 2 weeks | 35 |
| The value of melatonin supplementation in postmenopausal women with Helicobacter pylori-associated dyspepsia 2020 · Group IIIb (melatonin) · Postmenopausal women with chronic dyspepsia and Helicobacter pylori infection | 4 mg | 26 weeks | 32 |
| Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study 2005 · melatonin group · Patients with advanced gastrointestinal cancer, documented weight loss and/or decreased serum albumin, not amenable to standard anticancer treatment | 18 mg | 8 weeks | 11 |
| Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults 2012 · high dose 4 mg · Adults older than 65 with objective insomnia and low endogenous melatonin levels | 4 mg | 6 weeks | 10 |
| Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults 2012 · low dose 0.4 mg · Adults older than 65 with objective insomnia and low endogenous melatonin levels | 400 mcg | 6 weeks | 9 |
| Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial 2015 · 1 mg melatonin · Postmenopausal women with osteopenia, mean age 63 years (range 56–73) | 1 mg | 1 year | 20 |
| Different circulatory response to melatonin in postmenopausal women without and with hormone replacement therapy 2000 · melatonin, untreated postmenopausal women · postmenopausal women not receiving hormone replacement therapy | 1 mg | 1 day | — |
| Different circulatory response to melatonin in postmenopausal women without and with hormone replacement therapy 2000 · melatonin, postmenopausal women receiving hormone replacement therapy · postmenopausal women treated with transdermal estradiol and cyclic medroxyprogesterone acetate | 1 mg | 1 day | — |
| Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial 2019 · melatonin group · Adults with type 2 diabetes and coronary heart disease; age and sex not reported | 10 mg | 12 weeks | 30 |
| Effect of pharmacological daytime doses of melatonin on human mood and performance 1993 · 10 mg melatonin · Healthy male volunteers | 10 mg | 1 day | 20 |
| A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy 1999 · Capsule A (fast-release) · Healthy male volunteers | 5 mg | 1 day | 15 |
| A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy 1999 · Capsule B (pulsatile dosage form) · Healthy male volunteers | 10 mg | 1 day | 15 |
| A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy 1999 · Capsule C (pulsatile dosage form) · Healthy male volunteers | 10 mg | 1 day | 15 |
| Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis 2024 · 3 mg melatonin · Adults aged 18–65 with relapsing forms of multiple sclerosis receiving stable oral disease-modifying therapy | 3 mg | 1 year | 15 |
| Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis 2024 · 5 mg melatonin · Adults aged 18–65 with relapsing forms of multiple sclerosis receiving stable oral disease-modifying therapy | 5 mg | 1 year | 15 |
| Evaluation of an oral pulsatile delivery system for melatonin in humans 1998 · Capsule A (fast-release form) · Healthy male volunteers; age not reported | 5 mg | 1 day | 15 |
| Evaluation of an oral pulsatile delivery system for melatonin in humans 1998 · Capsule B (oral pulsatile delivery form) · Healthy male volunteers; age not reported | 10 mg | 1 day | 15 |
| Evaluation of an oral pulsatile delivery system for melatonin in humans 1998 · Capsule C (oral pulsatile delivery form) · Healthy male volunteers; age not reported | 10 mg | 1 day | 15 |
| Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia 2005 · Melatonin group (administration at 18:00 or 19:00) · Children aged 6–12 years with idiopathic chronic sleep onset insomnia | 5 mg | 4 weeks | — |
| The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial 2019 · intervention group · People with type 2 diabetes mellitus and chronic periodontitis; age and sex not specified | 6 mg | — | — |
| Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study 2024 · Treatment group · Adults younger than 60 years with COVID-19 or COVID-like illness, no previous medical history, and not hospitalized | 2 mg | — | 82 |
| A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study (MAVRICS) 2024 · melatonin treatment group · Healthy adults aged 18–64 years planning to receive influenza vaccination | 5 mg | 2 weeks | 53 |
| Exogenous melatonin boosts vaccine-induced immunity in individuals with high pre-existing influenza immunity 2025 · Melatonin treatment · Healthy adults aged 18–64 years receiving seasonal influenza vaccination; the reported high- and low-baseline HAI subgroups had elevated or lower pre-existing A/Victoria HAI titers, respectively. | 5 mg | 2 weeks | 53 |
| Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial 2022 · Melatonin · Adults aged 30–82 with symptomatic, clinically stable heart failure with reduced ejection fraction (NYHA class II or III) | 10 mg | 24 weeks | 46 |
| Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy 2021 · melatonin · Patients with diabetic nephropathy; age and sex not specified | 10 mg | 12 weeks | 30 |
| A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis 2019 · treatment group · patients with multiple sclerosis; age and sex not specified | 3 mg | 24 weeks | 25 |
| Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo-controlled study 2008 · melatonin · Healthy young men | 3 mg | 1 day | 24 |
| A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women 2015 · melatonin · Obese women; age not stated | 6 mg | 40 days | 22 |
| Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial 2025 · melatonin group · Adults aged 19–75 with chronic kidney failure undergoing continuous ambulatory peritoneal dialysis | 5 mg | 10 weeks | 22 |
| Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial 2026 · MLT group · Children aged 6–18 years with end-stage renal disease receiving maintenance hemodialysis | 5 mg | 12 weeks | 20 |
| The effect of preoperative melatonin on nuclear erythroid 2-related factor 2 activation in patients undergoing coronary artery bypass grafting surgery 2013 · Melatonin group (Group I) · Adults aged 41–75 undergoing elective coronary artery bypass grafting surgery | 10 mg | 30 days | 15 |
| 12-week melatonin intake attenuates cardiac autonomic dysfunction and oxidative stress in multiple sclerosis patients: a randomized controlled trial 2024 · melatonin group (MG) · People with multiple sclerosis; age range and sex not stated | 3 mg | 12 weeks | 15 |
| Effects of melatonin supplementation on serum oxidative stress markers and disease activity in systemic lupus erythematosus patients: A randomised, double-blind, placebo-controlled trial 2021 · melatonin group · Females with systemic lupus erythematosus (SLE); age not reported | 10 mg | 12 weeks | 13 |
| Phase advance with separate and combined melatonin and light treatment 2011 · melatonin · 11 subjects; age, sex, and health status not reported | 3 mg | 1 day | 11 |
| Phase advance with separate and combined melatonin and light treatment 2011 · melatonin plus light · 11 subjects; age, sex, and health status not reported | 3 mg | 1 day | 11 |
| The effect of melatonin administration on pituitary hormone secretion in man 1999 · 5.0 mg melatonin · Healthy men, mean age 21 years | 5 mg | 1 day | 8 |
| [Melatonin reduces cortisol response to ACTH in humans] 2008 · melatonin · Eight young healthy males pretreated with dexamethasone | 6 mg | 1 day | 8 |
| Melatonin enhances the luteinizing hormone and follicle-stimulating hormone responses to gonadotropin-releasing hormone in the follicular, but not in the luteal, menstrual phase 1995 · Melatonin during follicular phase · Normal cycling women studied during the follicular phase (cycle days 4–6) | 3 mg | 2 days | 8 |
| Melatonin enhances the luteinizing hormone and follicle-stimulating hormone responses to gonadotropin-releasing hormone in the follicular, but not in the luteal, menstrual phase 1995 · Melatonin during luteal phase · Normal cycling women studied during the luteal phase (cycle days 19–21) | 3 mg | 2 days | 8 |
| Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone 1993 · Study 1: oral melatonin · Normal males aged 22–35 years | 10 mg | 1 day | 8 |
| Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone 1993 · Study 3: oral melatonin · Normal males aged 22–35 years | 10 mg | 1 day | 8 |
| Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone 1993 · Study 3: melatonin plus pyridostigmine · Normal males aged 22–35 years | 10 mg | 1 day | 8 |
| Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone 1993 · Study 4: oral melatonin before submaximal GHRH · Normal males aged 22–35 years | 10 mg | 1 day | 8 |
| Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone 1993 · Study 4: melatonin plus pyridostigmine before submaximal GHRH · Normal males aged 22–35 years | 10 mg | 1 day | 8 |
| The hypothermic effect of melatonin on core body temperature: is more better? 1996 · 5.0 mg melatonin · Healthy adults aged 18–38 years | 5 mg | 1 day | 8 |
| Exercise-induced GH secretion is enhanced by the oral ingestion of melatonin in healthy adult male subjects 1999 · melatonin · Seven healthy adult male subjects | 5 mg | 1 day | 7 |
| Hypothermic action of exogenously administered melatonin is dose-dependent in humans 2001 · 3 mg exogenous melatonin · Healthy young men aged 19–24 years | 3 mg | 1 day | 6 |
| Hypothermic action of exogenously administered melatonin is dose-dependent in humans 2001 · 9 mg exogenous melatonin · Healthy young men aged 19–24 years | 9 mg | 1 day | 6 |
| Hypnotic and hypothermic action of daytime-administered melatonin 1997 · 3 mg melatonin condition · Healthy men, average age 22.5 years | 3 mg | 1 day | 6 |
| Hypnotic and hypothermic action of daytime-administered melatonin 1997 · 9 mg melatonin condition · Healthy men, average age 22.5 years | 9 mg | 1 day | 6 |
| Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil 1999 · placebo-melatonin · Six healthy young adult men | 3 mg | 1 day | — |
| Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil 1999 · flumazenil-melatonin · Six healthy young adult men | 3 mg | 1 day | — |
| Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients 1992 · IL-2 once daily plus MLT at 10 mg/day · Advanced cancer patients; age and sex not reported | 10 mg | 4 weeks | — |
| Melatonin administration to blind people: phase advances and entrainment 1991 · melatonin group · totally blind men with free-running endogenous melatonin rhythms | 5 mg | 3 weeks | — |
| Melatonin treatment for eastward and westward travel preparation 2010 · 3 mg regular release (RR) · Subjects; age, sex, and health status not specified | 3 mg | 1 day | — |
| Melatonin treatment for eastward and westward travel preparation 2010 · 3 mg sustained release (SR) · Subjects; age, sex, and health status not specified | 3 mg | 1 day | — |
| Combination of light and melatonin time cues for phase advancing the human circadian clock 2013 · dim light-melatonin · Healthy adults aged 22 ± 4 years; 18 of the 36 participants were female | 5 mg | 1 day | — |
| Combination of light and melatonin time cues for phase advancing the human circadian clock 2013 · bright light-melatonin · Healthy adults aged 22 ± 4 years; 18 of the 36 participants were female | 5 mg | 1 day | — |
| The protective effect of melatonin on smoke-induced vascular injury in rats and humans: a randomized controlled trial 2016 · melatonin · smokers; age and sex not specified | 3 mg | 2 weeks | — |
| Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients 2017 · melatonin group · Critically ill adults in an ICU with an estimated mechanical ventilation duration over 8 days | 6 mg | — | — |
| The protective effect of melatonin on brain ischemia and reperfusion in rats and humans: In vivo assessment and a randomized controlled trial 2018 · melatonin · Patients with carotid stenosis undergoing carotid endarterectomy; age and sex not stated | 6 mg | 6 days | — |
| Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study 2019 · ST-OS · High-risk critically ill patients | 3 mg | 1 day | — |
| Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study 2019 · SLN-OS · High-risk critically ill patients | 3 mg | 1 day | — |
| The effect of oral melatonin on renal ischemia-reperfusion injury in transplant patients: A double-blind, randomized controlled trial 2019 · melatonin group · Renal transplant candidates; age and sex not reported | 3 mg | — | — |
| Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients 2021 · EX + MEL · Hemodialysis patients; age and sex not reported | 3 mg | 1 day | — |
| Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients 2021 · CON + MEL · Hemodialysis patients; age and sex not reported | 3 mg | 1 day | — |
| Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans 1995 · 5 mg melatonin · 6 healthy volunteers; age and sex not reported | 5 mg | 1 day | — |
| Adapting to phase shifts, II. Effects of melatonin and conflicting light treatment 1996 · MT · volunteers; age, sex, and health condition not stated | 5 mg | 3 days | — |
| Adapting to phase shifts, II. Effects of melatonin and conflicting light treatment 1996 · MT+BL · volunteers; age, sex, and health condition not stated | 5 mg | 3 days | — |
| Effect of pharmacological daytime doses of melatonin on human mood and performance 1993 · 20 mg melatonin · Healthy male volunteers | 20 mg | 1 day | 20 |
| Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers 2022 · Oniria prolonged-release melatonin · Healthy men and women aged 20–45 years without relevant clinical conditions or analytical alterations | 1.98 mg | 1 day | 14 |
| Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers 2022 · Immediate-release melatonin (Melatoplus) · Healthy men and women aged 20–45 years without relevant clinical conditions or analytical alterations | 1.99 mg | 1 day | 14 |
| Dose assessment of melatonin in sepsis (DAMSEL2) study: Pharmacokinetics of two doses of oral melatonin in patients with sepsis 2022 · 20 mg dose cohort · Adults older than 16 with sepsis due to community-acquired pneumonia admitted to ICU or medical high dependency unit; four male and one female, aged 45–83 years | 20 mg | 1 day | 5 |
| The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study 2006 · melatonin without CYP2C19 substrate · Elderly psychogeriatric inpatients with insomnia, without a CYP2C19 substrate | 2 mg | 3 weeks | — |
| The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study 2006 · melatonin with CYP2C19 substrate · Elderly psychogeriatric inpatients with insomnia who were receiving a CYP2C19 substrate (citalopram, omeprazole, or lansoprazole) | 2 mg | 3 weeks | — |
| Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women 2012 · melatonin · Perimenopausal women aged 45–54 | 3 mg | 26 weeks | 13 |
| The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial 2019 · study group · Patients with rectal cancer undergoing radiotherapy | 20 mg | 4 weeks | 30 |
| Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia 2001 · melatonin alone · Patients with cancer-related thrombocytopenia who had not responded to melatonin alone | 20 mg | — | 16 |
| Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system 2002 · IL-2 plus MLT alone · Patients with untreatable metastatic solid tumors | 20 mg | 4 weeks | 14 |
| Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system 2002 · IL-2 plus MLT plus NTX · Patients with untreatable metastatic solid tumors | 20 mg | 4 weeks | 14 |
| The effect of melatonin on glucose tolerance, insulin sensitivity and lipid profiles after a late evening meal in healthy young males 2021 · DSC (dark + exogenous melatonin) · Healthy male students, mean age 26 years | 2 mg | 1 day | 9 |
| The effect of melatonin on glucose tolerance, insulin sensitivity and lipid profiles after a late evening meal in healthy young males 2021 · LSC (light + exogenous melatonin) · Healthy male students, mean age 26 years | 2 mg | 1 day | 9 |
| Robust circadian rhythm in heart rate and its variability: influence of exogenous melatonin and photoperiod 2007 · Melatonin · Healthy males, mean age 24.4 years | 1.5 mg | 9 days | 8 |
| Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin 2015 · melatonin · Men with stable, complete tetraplegia; age range not reported | 2 mg | 4 days | 6 |
| Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study 2015 · melatonin supplementation · Six men with long-standing complete tetraplegia | 2 mg | 4 days | 6 |
| Amplification of pulsatile LH secretion by exogenous melatonin in women 1991 · 2.5 mg melatonin in three divided doses group · Women in the early follicular phase (cycle days 2–5) | 2.5 mg | 2 days | 5 |
| Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin 2006 · melatonin and zinc alone · Patients with type 2 diabetes mellitus and inadequate response to metformin | 10 mg | 90 days | — |
| Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin 2006 · melatonin and zinc with metformin · Patients with type 2 diabetes mellitus and inadequate response to metformin | 10 mg | 90 days | — |
| Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up 2014 · Group II · Patients with NAFLD confirmed by liver biopsy; age and sex not reported | 10 mg | 426 days | — |
| Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin 1997 · chemotherapy plus MLT · Patients with metastatic solid tumors in poor clinical condition: lung cancer, breast cancer, or gastrointestinal tract tumors; age and sex not reported | 20 mg | — | — |
| Antioxidant Effect of Melatonin in Preterm Newborns 2021 · MEL group · Preterm newborns born before 37 weeks’ gestation | 0.5 mg/kg | 7 days | 21 |
| Effect of pharmacological daytime doses of melatonin on human mood and performance 1993 · 40 mg melatonin · Healthy male volunteers | 40 mg | 1 day | 20 |
| Effect of pharmacological daytime doses of melatonin on human mood and performance 1993 · 80 mg melatonin · Healthy male volunteers | 80 mg | 1 day | 20 |
| Effect of Red Wine Intake on Serum and Salivary Melatonin Levels: A Randomized, Placebo-Controlled Clinical Trial 2018 · MLT+ wine · Healthy, normal-weight adults aged 20–45 years; seven males and five females were recruited | 1.25 mcg | 1 day | 12 |
| Dose assessment of melatonin in sepsis (DAMSEL2) study: Pharmacokinetics of two doses of oral melatonin in patients with sepsis 2022 · 50 mg dose cohort · Adults older than 16 with sepsis due to community-acquired pneumonia admitted to ICU or medical high dependency unit; all male, aged 54–70 years | 50 mg | 1 day | 5 |
| Feasibility and functionality of OROS melatonin in healthy subjects 1999 · 1 × 110 micrograms · Healthy adults aged 60–73 years with no sleep disorders | 110 mcg | 1 day | — |
| Feasibility and functionality of OROS melatonin in healthy subjects 1999 · 4 × 110 micrograms · Healthy adults aged 60–73 years with no sleep disorders | 110 mcg | 1 day | — |
| Effects of Melatonin and Propolis Supplementation on Inflammation, Oxidative Stress, and Clinical Outcomes in Patients with Primary Pneumosepsis: A Randomized Controlled Clinical Trial 2022 · melatonin alone · Patients with primary pneumosepsis; age and sex not reported | 20 mg | — | — |
| Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease 2020 · melatonin · Patients with stage 1–3 Parkinson's disease | 50 mg | 90 days | 26 |
| Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial 2020 · MT · Adults of either sex with septic shock | 50 mg | 5 days | 20 |
| Acute metabolic effects of melatonin-A randomized crossover study in healthy young men 2021 · Melatonin · Healthy young men | 40 mg | 1 day | 20 |
| Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT 2010 · 0.1 mg/kg melatonin group · Children aged 6–12 years with chronic sleep onset insomnia | 0.1 mg/kg | 7 days | 19 |
| Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT 2010 · 0.15 mg/kg melatonin group · Children aged 6–12 years with chronic sleep onset insomnia | 0.15 mg/kg | 7 days | 18 |
| Melatonin ameliorates inflammation and improves outcomes of ischemia/reperfusion injury in patients undergoing coronary artery bypass grafting surgery: a randomized placebo-controlled study 2025 · Melatonin-treated group (MTG) · Adults undergoing elective on-pump coronary artery bypass grafting surgery; ages 56.6 ± 8.031 years in the melatonin group; patients with coronary heart disease | 60 mg | 5 days | 17 |
| Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT 2010 · 0.05 mg/kg melatonin group · Children aged 6–12 years with chronic sleep onset insomnia | 0.05 mg/kg | 7 days | 16 |
| Essential Hypertension and Oxidative Stress: Novel Future Perspectives 2022 · melatonin group · Adults aged 40–60 years with essential hypertension | 1 mg | 1 year | 16 |
| Influence of exogenous melatonin on catecholamine levels in postmenopausal women prior and during oestradiol replacement 2000 · melatonin · Healthy postmenopausal women | 1 mg | 1 day | 14 |
| Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia 2001 · melatonin plus 5-methoxytryptamine · Patients with cancer-related thrombocytopenia who had not responded to melatonin alone | 20 mg | — | 14 |
| Melatonin prevents oxidative stress resulting from iron and erythropoietin administration 2001 · Melatonin with recombinant human erythropoietin · Adults with end-stage renal failure receiving chronic hemodialysis | 0.3 mg/kg | 1 day | 9 |
| The effect of melatonin administration on pituitary hormone secretion in man 1999 · 0.05 mg melatonin · Healthy men, mean age 21 years | 50 mcg | 1 day | 8 |
| The effect of melatonin administration on pituitary hormone secretion in man 1999 · 0.5 mg melatonin · Healthy men, mean age 21 years | 500 mcg | 1 day | 8 |
| Melatonin enhances cortisol levels in aged but not young women 1995 · melatonin, aged women · Women aged 54–62 years who were postmenopausal | 100 mg | 2 days | 8 |
| The hypothermic effect of melatonin on core body temperature: is more better? 1996 · 0.1 mg melatonin · Healthy adults aged 18–38 years | 100 mcg | 1 day | 8 |
| The hypothermic effect of melatonin on core body temperature: is more better? 1996 · 0.5 mg melatonin · Healthy adults aged 18–38 years | 500 mcg | 1 day | 8 |
| The hypothermic effect of melatonin on core body temperature: is more better? 1996 · 1.0 mg melatonin · Healthy adults aged 18–38 years | 1 mg | 1 day | 8 |
| Melatonin enhances cortisol levels in aged women: reversible by estrogens 1997 · melatonin · Seven aged postmenopausal women | 100 mg | 2 days | 7 |
| Hypothermic action of exogenously administered melatonin is dose-dependent in humans 2001 · 0.5 mg exogenous melatonin · Healthy young men aged 19–24 years | 500 mcg | 1 day | 6 |
| Amplification of pulsatile LH secretion by exogenous melatonin in women 1991 · 100 mg single-dose melatonin group · Women in the early follicular phase (cycle days 2–5) | 100 mg | 2 days | 6 |
| Melatonin enhances cortisol levels in aged but not young women 1995 · melatonin, young women · Women aged 22–32 years in the early follicular phase | 100 mg | 2 days | 6 |
| Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy 2001 · melatonin · Postmenopausal women, including women with and without hormone replacement therapy | 1 mg | 1 day | — |
| Effects of exogenous melatonin on pituitary hormones in humans 2001 · exogenous melatonin · Healthy adults and patients with sleep disorders; ages and sex not specified | 1 mg | 1 day | — |
| Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients 1992 · IL-2 once daily plus MLT at 50 mg/day · Advanced cancer patients; age and sex not reported | 50 mg | 4 weeks | — |
| The benefit of a supplement with the antioxidant melatonin on redox status and muscle damage in resistance-trained athletes 2017 · melatonin · Resistance-trained athletes | 100 mg | 4 weeks | — |
| [Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease] 2017 · MEL · Patients with Parkinson's disease | 50 mg | 1 year | — |
| Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis 2018 · experimental group · Adults with relapsing-remitting multiple sclerosis treated with interferon β-1b | 25 mg | 26 weeks | — |
| Melatonin a Promising Candidate for DNA Double-Stranded Breaks Reduction in Patients Undergoing Abdomen-Pelvis Computed Tomography Examinations 2020 · group two · Patients undergoing abdomen-pelvis CT examinations | 100 mg | 1 day | — |
| Effects of chronotherapy on circadian rhythm and ADHD symptoms in adults with attention-deficit/hyperactivity disorder and delayed sleep phase syndrome: a randomized clinical trial 2021 · melatonin · Adults aged 18–55 with ADHD and delayed sleep phase syndrome | 500 mcg | 3 weeks | — |
| Effects of chronotherapy on circadian rhythm and ADHD symptoms in adults with attention-deficit/hyperactivity disorder and delayed sleep phase syndrome: a randomized clinical trial 2021 · melatonin plus bright light therapy · Adults aged 18–55 with ADHD and delayed sleep phase syndrome | 500 mcg | 3 weeks | — |
| Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson's Disease 2021 · melatonin-placebo group (melatonin phase) · Adults over 20 years old with stage 1–3 Parkinson's disease | 50 mg | 90 days | — |
| The efficacy of melatonin against radiotoxicity of iodine-131 and its response to treatment in hyperthyroid patients: a randomized controlled trial 2022 · melatonin group · female patients with hyperthyroidism | 300 mg | 1 day | — |
| Effects of Melatonin and Propolis Supplementation on Inflammation, Oxidative Stress, and Clinical Outcomes in Patients with Primary Pneumosepsis: A Randomized Controlled Clinical Trial 2022 · propolis plus melatonin · Patients with primary pneumosepsis; age and sex not reported | 20 mg | — | — |
| Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin 1994 · TNF plus MLT · patients with metastatic solid tumors for whom no effective standard antitumor therapy was available | 40 mg | 12 days | — |
| Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans 1995 · 0.05 mg melatonin · 6 healthy volunteers; age and sex not reported | 50 mcg | 1 day | — |
| Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans 1995 · 0.5 mg melatonin · 6 healthy volunteers; age and sex not reported | 500 mcg | 1 day | — |
| Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients 1995 · Low-dose IL-2 plus melatonin · Patients with gastrointestinal tract tumors undergoing surgery; age and sex not reported | 40 mg | 5 days | — |
| Influences of melatonin administration on the circulation of women 1998 · melatonin · 17 young, healthy, early follicular-phase women | 1 mg | 1 day | — |
| Myo-inositol and melatonin in the menopausal transition 2017 · myo-inositol plus melatonin group · Women aged 45–55 years with at least 6 months of amenorrhea during the menopausal transition | 3 g | 26 weeks | 20 |
| Melatonin prevents oxidative stress resulting from iron and erythropoietin administration 2001 · Melatonin with intravenous iron · Adults with end-stage renal failure receiving chronic hemodialysis | 0.3 mg/kg | 1 day | 9 |
| Contemporaneous melatonin administration modifies the circadian response to nocturnal bright light stimuli 1997 · melatonin · Women; no age range or condition reported | 1.75 mg | 3 days | 5 |
| New chitin complexes and their anti-aging activity from inside out 2012 · ORAL MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · ORAL CN-MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group A · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 3 mg | — | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · COMBINED MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · COMBINED CN-MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |